E Fund Management Co. Ltd. Has $4.13 Million Stock Position in STAAR Surgical (NASDAQ:STAA)

E Fund Management Co. Ltd. lessened its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 83.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,296 shares of the medical instruments supplier’s stock after selling 650,000 shares during the quarter. E Fund Management Co. Ltd. owned approximately 0.27% of STAAR Surgical worth $4,129,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Clear Street Markets LLC purchased a new stake in STAAR Surgical in the 3rd quarter worth approximately $29,000. Nisa Investment Advisors LLC increased its position in STAAR Surgical by 415.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,445 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 1,971 shares during the last quarter. Covestor Ltd lifted its holdings in shares of STAAR Surgical by 82,466.7% during the 3rd quarter. Covestor Ltd now owns 2,477 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 2,474 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of STAAR Surgical by 44.5% in the 3rd quarter. Van ECK Associates Corp now owns 3,184 shares of the medical instruments supplier’s stock valued at $128,000 after buying an additional 980 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in STAAR Surgical by 171.5% in the third quarter. PNC Financial Services Group Inc. now owns 3,755 shares of the medical instruments supplier’s stock worth $151,000 after buying an additional 2,372 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analyst Upgrades and Downgrades

STAA has been the topic of several analyst reports. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research note on Wednesday. Piper Sandler upped their price target on STAAR Surgical from $33.00 to $40.00 and gave the stock a “neutral” rating in a research note on Wednesday. Canaccord Genuity Group reduced their target price on STAAR Surgical from $46.00 to $43.00 and set a “hold” rating for the company in a report on Wednesday. William Blair raised shares of STAAR Surgical from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 4th. Finally, Mizuho upped their price objective on shares of STAAR Surgical from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $47.13.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, Director Aimee S. Weisner bought 1,750 shares of the stock in a transaction dated Thursday, March 14th. The stock was bought at an average cost of $38.11 per share, for a total transaction of $66,692.50. Following the completion of the purchase, the director now owns 10,864 shares in the company, valued at approximately $414,027.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.00% of the company’s stock.

STAAR Surgical Trading Up 4.5 %

NASDAQ:STAA traded up $1.84 during mid-day trading on Thursday, hitting $42.86. The company’s stock had a trading volume of 809,384 shares, compared to its average volume of 734,185. The stock has a fifty day moving average of $42.13 and a 200-day moving average of $35.87. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of 95.40 and a beta of 0.80. STAAR Surgical has a fifty-two week low of $26.66 and a fifty-two week high of $68.27.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The company had revenue of $77.40 million during the quarter, compared to analyst estimates of $75.34 million. During the same period in the prior year, the firm earned $0.05 EPS. STAAR Surgical’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities analysts anticipate that STAAR Surgical will post 0.03 earnings per share for the current fiscal year.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.